TW200509906A - Crystalline 1-methylcarbapenem compounds - Google Patents

Crystalline 1-methylcarbapenem compounds

Info

Publication number
TW200509906A
TW200509906A TW093125423A TW93125423A TW200509906A TW 200509906 A TW200509906 A TW 200509906A TW 093125423 A TW093125423 A TW 093125423A TW 93125423 A TW93125423 A TW 93125423A TW 200509906 A TW200509906 A TW 200509906A
Authority
TW
Taiwan
Prior art keywords
crystalline
methylcarbapenem compounds
crystal
methylcarbapenem
compounds
Prior art date
Application number
TW093125423A
Other languages
English (en)
Inventor
Makoto Michida
Yuki Nagao
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200509906A publication Critical patent/TW200509906A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW093125423A 2003-08-25 2004-08-25 Crystalline 1-methylcarbapenem compounds TW200509906A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003299677 2003-08-25

Publications (1)

Publication Number Publication Date
TW200509906A true TW200509906A (en) 2005-03-16

Family

ID=34213774

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093125423A TW200509906A (en) 2003-08-25 2004-08-25 Crystalline 1-methylcarbapenem compounds

Country Status (9)

Country Link
US (1) US7534782B2 (zh)
EP (1) EP1659122A4 (zh)
KR (1) KR20060122810A (zh)
CN (3) CN101284831A (zh)
BR (1) BRPI0413842A (zh)
CA (2) CA2536886C (zh)
IL (1) IL173631A0 (zh)
TW (1) TW200509906A (zh)
WO (1) WO2005019217A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2602097A1 (en) * 2005-03-22 2006-09-28 Daiichi Sankyo Company, Limited Process for producing carbapenem derivatives having 1-alkylpyrrolidine structure
TW200639176A (en) * 2005-05-13 2006-11-16 Sankyo Co Crystal of 1-methyl carbapenem compound
CN101357918B (zh) * 2007-06-22 2011-05-18 山东轩竹医药科技有限公司 含有异硫脲基巯基吡咯烷的培南衍生物
CN103298813B (zh) * 2010-12-16 2016-09-14 珠海亿邦制药股份有限公司 碳青霉烯衍生物的无定形粉末和多晶型物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ324447A (en) * 1995-12-21 1999-08-30 Sankyo Co 1-methyl-carbapenem substituted by a 4-pyrrolidinylthio group and medicaments
JP2965922B2 (ja) 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
JP2955276B2 (ja) 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
TWI250160B (en) 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound
US7041660B2 (en) 1999-07-06 2006-05-09 Sankyo Company, Limited Crystalline 1-methylcarbapenem derivatives
JP2001114759A (ja) * 1999-08-12 2001-04-24 Sankyo Co Ltd メルカプトピロリジン誘導体
JP3681116B2 (ja) * 2000-09-14 2005-08-10 三共株式会社 結晶性カルバペネム化合物を含有する抗菌剤
TW200639176A (en) * 2005-05-13 2006-11-16 Sankyo Co Crystal of 1-methyl carbapenem compound

Also Published As

Publication number Publication date
US20060189592A1 (en) 2006-08-24
CN101284830A (zh) 2008-10-15
CN101284831A (zh) 2008-10-15
BRPI0413842A (pt) 2006-10-24
US7534782B2 (en) 2009-05-19
CN100475817C (zh) 2009-04-08
CN1842531A (zh) 2006-10-04
EP1659122A1 (en) 2006-05-24
CA2536886A1 (en) 2005-03-03
WO2005019217A1 (ja) 2005-03-03
KR20060122810A (ko) 2006-11-30
EP1659122A4 (en) 2010-06-16
CA2644316A1 (en) 2005-03-03
CA2536886C (en) 2009-10-27
IL173631A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
GEP20105086B (en) Potassium salt of an hiv integrase inhibitor
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
UA93531C2 (en) Novel hydrogen sulfate salt
UA83718C2 (ru) Кристаллическая форма iv агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
UA83720C2 (ru) Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
EA200300107A1 (ru) Кристаллические формы трет-бутиламиновой соли периндоприла
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
RS51954B (en) CRYSTAL MODIFICATIONS OF PYRACLOSTROBIN
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
RS20050810A (en) 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
EA200601274A1 (ru) Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
TNSN07165A1 (en) Organic compounds
TW200420541A (en) Crystalline forms
HRP20110641T1 (en) Crystalline modification of fipronil
UA89905C2 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
MXPA05009303A (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
PT1656381E (pt) Cristalização de formas sólidas de sais de adição de clopidogrel
TW200509906A (en) Crystalline 1-methylcarbapenem compounds
WO2006053625A8 (en) Crystalline form of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
EP1880997A4 (en) 1-METHYLCARBAPENEM COMPOUND CRYSTAL
MY142738A (en) Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt
TNSN05076A1 (en) New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
TNSN05077A1 (en) New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it